Tracers / [177Lu]Lu-OncoFAP
[177Lu]Lu-OncoFAP
Also written as OncoFAP; Lu-177-OncoFAP
- Radionuclide
- Lu-177 t½ 9584.6 min
- Modality
- Therapy
- Production route
- —
- Stage
- preclinical
- Syntheses indexed
- 0
What it is
- Compound class
- FAP-targeted small organic radioligand (quinoline-based FAP inhibitor)
- Target / mechanism
- Fibroblast activation protein (FAP) PMID 36015106
- Clinical application
- Patients with FAP-positive solid tumors, for radioligand therapy PMID 39266289
- Theranostic pair
- <a href="/tracers/ga68-oncofap/">ga68-oncofap</a>
Regulatory status
- FDA
- —
- EMA (centralised)
- —
- Other approvals
- —
- Brand names
- —
Clinical use
- Typical injected activity
- —
- Uptake time
- —
Reported in the literature. Not a dosing recommendation.
Published syntheses
No synthesis has been parsed for this agent yet.
Need this precursor?We can point you to suppliers for [177Lu]Lu-OncoFAP, or handle the enquiry for you.
Get in touchNotes
Added at stage 21 from therapy-discovered.xlsx (bulk PubMed search by isotope/therapy-type/known-agent, not individually researched yet) -- 2 articles found. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Diagnostic pair signal at discovery: YES - Ga-68.